NanoRepro AG

XETRA NN6.DE

NanoRepro AG EBT Margin for the year ending December 31, 2023: -144.28%

NanoRepro AG EBT Margin is -144.28% for the year ending December 31, 2023, a -1,172.34% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • NanoRepro AG EBT Margin for the year ending December 31, 2022 was -11.34%, a -147.61% change year over year.
  • NanoRepro AG EBT Margin for the year ending December 31, 2021 was 23.82%, a 45.02% change year over year.
  • NanoRepro AG EBT Margin for the year ending December 31, 2020 was 16.42%, a 116.84% change year over year.
  • NanoRepro AG EBT Margin for the year ending December 31, 2019 was -97.55%, a -710.96% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
SV Wall Street
XETRA: NN6.DE

NanoRepro AG

Description

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.

Similar companies

F3C.DE

SFC Energy AG

USD 17.19

-2.70%

StockViz Staff

February 5, 2025

Any question? Send us an email